4.12 Real-World Survival Outcomes for Pertuzumab and T-DM1 with Dr. Josee-Lyne Ethier

from Plenary Session - inactive due to federal service · host Vinay Prasad, MD MPH

Today we interview Dr. Josee-Lyne Ethier of Queen's University in Kingston, Ontario, Canada on her new paper "Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer", out now in JAMA Oncology. We talk about the real-world survival outcomes for pertuzumab and T-DM1, comparing these outcomes to the results of pivotal clinical trials CLEOPATRA and EMILIA. Practice Patterns and Outcomes: doi.org/10.1001/jamaoncol.2021.2140 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Episode metadata supplied by the publisher feed · Published Aug 3, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

4.12 Real-World Survival Outcomes for Pertuzumab and T-DM1 with Dr. Josee-Lyne Ethier

0:00 35:50

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Plenary Session - inactive due to federal service?

This episode is 35 minutes long.

When was this Plenary Session - inactive due to federal service episode published?

This episode was published on August 3, 2021.

Can I download this Plenary Session - inactive due to federal service episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!